Shulan Health Startup Diligence Report
Proceed only to confirmatory diligence. The core thesis depends on proving that Shulan can convert high-acuity private-hospital brand and digital-health ambitions into sustainable, subsidy-adjusted profitability despite医保/DRG pressure, expansion capex, governance/share-freeze concerns and strong competition from public hospitals and private specialty networks.
Shulan Health Startup Diligence Report
Shulan Health appears to remain an eligible private-unicorn diligence target based on the current CB Insights row and no public evidence of completed IPO, acquisition or shutdown in the sources reviewed. Public evidence supports a real healthcare-provider network with hospital, management, platform, internet-hospital and AI/digital initiatives, but investment-grade diligence remains unresolved because audited financials, current cap table, contracts, payer economics, legal dockets, licenses, HR and IP schedules are not public.
Public media reports revenue scale but continuing losses and high leverage; 2023 loss improvement may depend on an RMB 80M government subsidy.
Diligence request: Review audited financials, debt maturities, cash runway, subsidy accounting, budget-to-actuals and facility-level EBITDA.
Private hospitals can access医保, but医保-covered services face pricing guidance, payment reform and dynamic supervision.
Diligence request: Quantify payer mix, DRG/DIP settlement exposure, denial rates,医保 audits and scenario sensitivity to reimbursement cuts.
CB Insights and media support a unicorn valuation screen, but the IPO process reportedly stalled and current financing terms are not public.
Diligence request: Request current cap table, preference stack, latest 409A/valuation materials, IPO correspondence and investor side letters.
New hospitals appear to be in ramp-up while historic revenue was concentrated in the Hangzhou flagship.
Diligence request: Request site-level revenue, occupancy, physician utilization, quality metrics, capex budgets and ramp-to-profitability model.
The group is controlled through Shanghai Shulan Investment; media reports an equity freeze and family succession dynamics.
Diligence request: Have counsel verify freeze status, related-party transactions, board independence, shareholder agreements and control covenants.
The business depends on hospital licenses, transplant qualifications, GCP/clinical-trial compliance, internet-hospital approvals and医保 management.
Diligence request: Request license register, agency inspection history, quality incidents, malpractice claims, clinical-trial compliance files and adverse-event logs.
Shulan competes against public tertiary hospitals, broad private networks, oncology/specialty chains and digital-health platforms.
Diligence request: Build local market share, referral win/loss and pricing benchmarks by service line and geography.
AI/online-hospital strategy is public, but product adoption, model validation, cybersecurity, data consent and IP ownership are not public.
Diligence request: Review product analytics, ML governance, cybersecurity audits, data-processing agreements, software ownership and AI clinical-safety controls.
Shulan has public unicorn and financing anchors plus prospectus-cited revenue scale, but primary financial statements, debt schedules, cap table terms and forecast support are not public.
partially verified confidence: medium
Public articles citing prospectus data provide revenue, loss and leverage signals for 2020-2023, but audited statements, footnotes, AR aging, backlog and budget-to-actuals are not public.
| period | revenue rmb | profit loss rmb | liabilities or margin | verification status |
|---|---|---|---|---|
| 2020 | RMB 1.618B | Profit RMB 64.1M | Hangzhou hospital revenue share reported at 74.0% | partially_verified |
| 2021 | RMB 1.548B | Loss RMB 82.3M / 82.289M reported | Liabilities RMB 3.226B; asset-liability ratio 100%; health-medical-service gross margin 9.6% | partially_verified |
| 2022 | RMB 1.778B | Loss RMB 110.9M / 111M reported | Liabilities RMB 3.691B; asset-liability ratio 103%; health-medical-service gross margin 8.5% | partially_verified |
| 2023 | RMB 1.884B | Loss RMB 17.252M reported | Liabilities RMB 2.607B; asset-liability ratio 68%; loss improvement reportedly aided by RMB 80M subsidy | partially_verified |
| Private-data request | Audited revenue by product, payer and facility | EBITDA, cash flow and subsidy-adjusted earnings | Debt maturity, capex, AR aging and covenant package | not_publicly_verifiable |
Public numbers are secondary-source summaries of prospectus data, not audited statements provided to this diligence run.
not publicly verifiable confidence: low
No public three-year forecast was available. Public evidence points to growth drivers from hospital ramp, digital services and management-output services, offset by医保 pricing and DRG/DIP risk.
| item | public signal | risk or gap | source |
|---|---|---|---|
| 医保-covered services, drugs and consumables | Private provider still follows local pricing guidance for医保-covered items according to media citing prospectus. | Limits pricing freedom and gross margin expansion. | Eastmoney/Blue Whale |
| Health-medical-service gross margin | Reported 9.6% in 2021 and 8.5% in 2022. | Low margin needs validation by service line and subsidy treatment. | Eastmoney/Blue Whale |
| Average inpatient spend | Reported decline from RMB 21,300 in 2021 to RMB 17,500 in 2023. | Could reflect reimbursement pressure, mix shift or strategy. | Eastmoney/Blue Whale |
| DRG/DIP reform | NHSA targets coverage of eligible inpatient institutions by 2025. | Requires margin scenario analysis under payment reform. | Gov.cn / NHSA |
| Product-level unit economics | Not publicly disclosed. | Request revenue, gross margin, utilization and contribution by product/service. | Public gap ledger |
Pricing table intentionally mixes reported data and diligence-request rows because detailed price books are private.
partially verified confidence: medium
CB Insights and CICC provide public valuation/shareholder anchors, but the current fully diluted cap table, preference stack, debt and option pool are not public.
| date | event | public amount | valuation | investors or source | verification status |
|---|---|---|---|---|---|
| 2013-11-26 | Company founded | N/A | Not public | CICC company basics | verified |
| Pre-2021 | Five financing rounds reported in public media | More than RMB 800M / nearly RMB 900M reported | Not independently verified by round | 36Kr; Eastmoney/Blue Whale | partially_verified |
| 2021-03 | D round / unicorn-list join month | RMB 200M reported | RMB 8.0B reported; CB Insights $1.24B | Qiming listed by CB Insights; other public investors include Sequoia-related and GIC-linked holders in CICC table | partially_verified |
| 2026-05-23 | Current unicorn-list screen | N/A | $1.24B | CB Insights unicorn list | verified |
Round terms, share classes and preference economics are not public.
| stakeholder | public position | ownership percent | diligence caveat |
|---|---|---|---|
| Shanghai Shulan Investment Co., Ltd. | Controlling shareholder | 46.9067% | Verify freeze, pledges, transfers and control covenants. |
| Zheng Jie / Zheng Jun through Shanghai Shulan Investment | Actual controller / family control | 60% / 40% of Shanghai Shulan Investment in 2021 | Verify current ownership and related-party arrangements. |
| Cliff Investment Pte. Ltd. / GIC-linked | Large institutional shareholder | 13.9337% | Confirm current stake, rights and any transfer after 2021. |
| Suzhou Qiming Rongxin | Investor; CB Insights selected investor source also names Qiming Venture Partners | 2.2107% | Confirm fund relationship and rights. |
| Shenzhen Sequoia Hanhchen | Sequoia-related investor | 2.1866% | Confirm current stake and liquidation preferences. |
Snapshot is 2021 and likely incomplete for current preferred shares, options, debt, pledges or freezes.
Not a mark-to-market valuation.
partially verified confidence: medium
Public sources disclose financing history and some reported profitability but not tax positions, accounting policies, revenue recognition, debt covenants or working-capital arrangements.
Shulan offers healthcare services through hospitals plus hospital-management/platform and internet/digital services; product-market evidence is strongest for clinical service breadth and weakest for digital adoption and profitability.
partially verified confidence: medium
The public product set spans self-operated hospital care, hospital management output, platform/digital services, internet-hospital services, clinical trials and AI health tools; pricing, growth and profitability by product are not public.
| product or service | audience | public evidence | monetization or gap | verification status |
|---|---|---|---|---|
| Self-operated comprehensive hospital services | Patients,医保/commercial payers, referring physicians | Tertiary Grade A Hangzhou hospital with 46 clinical and 13 medical-technology departments; transplant capabilities. | Facility-level revenue/margin and outcomes are private. | verified |
| Hospital management services | Partner hospitals and local medical institutions | CICC describes cooperation in Fujian, Hainan, Chongqing and Zhengzhou. | Contract economics and renewal status not public. | partially_verified |
| Platform services / medical cloud | Internal network and partner facilities | CICC describes a group medical cloud platform and digital exploration. | SaaS/platform revenue, uptime and security not public. | partially_verified |
| Internet hospital and online pharmacy information services | Patients seeking online follow-up, reports or prescription support | Internet hospital page displays ICP and internet drug information service certificate. | User volume and transaction revenue not public. | verified |
| AI health agent Dr.Shu and AI future hospital | Patients, clinicians and care managers | China News profile reports 2025 Dr.Shu launch and AI future hospital plan. | Clinical validation, adoption and regulatory path not public. | partially_verified |
Product economics are mostly private; table reflects public existence and positioning only.
Conceptual architecture, not a verified technical architecture.
Public evidence supports patient-service activity and partnership claims, but top customers, payer concentration, reference calls, churn, referral-source economics and supplier contracts remain private.
not publicly verifiable confidence: low
For a provider network, “customers” are primarily patients, payers and referring institutions. Public sources do not disclose top 15 customers or payer accounts.
| segment | public signal | what it does not verify | verification status |
|---|---|---|---|
| Patients at Hangzhou flagship | Official materials claim outpatient/emergency and surgery volumes have steadily increased and satisfaction exceeds 95%. | Patient retention, clinical outcomes, payer mix or independent satisfaction methodology. | partially_verified |
| 医保-covered patients | Hangzhou hospital says it is医保 designated and national/provincial settlement capable. | 医保 revenue share, denials, audits or reimbursement lag. | partially_verified |
| Online/internet-hospital users | Internet hospital landing page is public. | MAU, online consultations, conversion or retention. | verified |
| Top 15 customers/payers/referrers | Not publicly disclosed. | Customer concentration, churn, referenceability and contract terms. | not_publicly_verifiable |
No patient-identifiable information is included.
No patient-identifiable data.
partially verified confidence: medium
Public sources identify partner-hospital output and international/academic collaboration claims, but contracts, exclusivity and revenue contribution are not public.
| partner or category | nature | public evidence | gap |
|---|---|---|---|
| Medical institutions in Fujian, Hainan, Chongqing and Zhengzhou | Hospital-management/medical-platform cooperation | CICC says Shulan cooperated with medical institutions in these regions. | Contracts, activity status and revenue not public. |
| UCLA, Massachusetts General Hospital, Princeton, HKU, Hong Kong Union Hospital, Macau University of Science and Technology | Officially claimed international cooperation and expert collaboration | Hospital intro lists these organizations. | Partner-side confirmation and contracts not obtained. |
| OMAHA / open medical and health alliance | Digital/standards ecosystem initiated by Zheng Jie | China News profile describes OMAHA and terminology set. | Legal relationship, IP and adoption not public. |
| 医保 agencies and commercial payers | Payer access and reimbursement | Private hospitals may apply for医保; Shulan Hangzhou says it is医保 designated. | Contracts, payer mix, audits and settlement lags not public. |
Partnership rows are public claims, not proof of active economic contribution.
not publicly verifiable confidence: low
Revenue concentration by payer, employer, insurer, referral network or patient segment is not public; public materials only disclose facility concentration in older prospectus-cited summaries.
not publicly verifiable confidence: low
No public evidence identified severed customer, payer, partner or supplier relationships, but this cannot be verified without contracts and management representations.
not publicly verifiable confidence: low
Supplier concentration is not public. Likely dependencies include physicians, equipment vendors, drugs/consumables,医保 settlement systems, cloud/IT vendors and construction contractors.
| dependency | role | public evidence | concentration risk |
|---|---|---|---|
| Physicians and clinical leaders | Patient acquisition, quality and complex-care delivery | Leadership roster and specialty claims are public. | Request key-clinician contracts, productivity and retention. |
| Medical equipment and consumables | High-acuity care, transplant, imaging and surgery | Hospital intro lists PET-CT, DSA, ECMO and da Vinci robot but not suppliers. | Request vendor contracts, maintenance, uptime and procurement spend. |
| 医保 payment and settlement systems | Reimbursement for covered inpatient/outpatient services | Policy sources describe医保定点 and DRG/DIP management. | Request payer settlement aging, denial rates and audits. |
| Cloud, HIS, AI and data infrastructure | Digital platform, online hospital and AI services | Hospital and profile sources describe cloud, big data, AI, IoT, HIS and Dr.Shu. | Request vendor list, data-processing agreements, security reports and source-code ownership. |
No top-supplier spend data was public.
Shulan competes in a fragmented but regulated Chinese healthcare market against public tertiary hospitals, broad private networks, specialty private chains and digital-health players.
partially verified confidence: medium
Shulan’s differentiated claim is a broad, high-acuity, research-oriented private-hospital model with digital services; competitors include public hospitals, United Family, Hygeia, AIER and digital-health platforms.
| competitor | segment | public scale or signal | product overlap | differentiator |
|---|---|---|---|---|
| Public tertiary hospitals in Zhejiang/China | General and specialty complex care | Not individually sourced in this public screen | High for complex inpatient, specialist and医保 services | Public trust, subsidies, referral network; Shulan differentiates on private/social-run model and service experience. |
| United Family Healthcare | Private general hospitals and clinics in major cities | Locations page lists Beijing, Shanghai, Guangzhou, Tianjin, Qingdao, Shenzhen and Hong Kong. | Private inpatient/outpatient, international/service-oriented care | International premium private-care brand and multi-city network. |
| Hygeia Healthcare | Oncology-focused healthcare group | Official site calls Hygeia the largest oncology healthcare group in China. | Oncology and hospital management/operation | Specialized oncology focus and listed-company investor disclosures. |
| AIER Eye Hospital Group | Ophthalmology specialty chain | Official profile states 881 hospitals/centers/clinics under AIER brand as of 2023-12-31. | Specialty outpatient/surgery economics; limited direct general-hospital overlap | Scaled specialty chain and public listing. |
| Digital-health platforms | Online consultation, appointment and health-management front door | Shulan itself has internet-hospital and AI-agent claims; peer platform metrics not sourced in this report. | Online front door and follow-up services | Digital-only players may scale faster; Shulan combines physical hospitals and digital services. |
No market share estimates were included because reliable public local share data was not found.
| axis | shulan public position | peer pressure | evidence or gap |
|---|---|---|---|
| Clinical breadth and high-acuity services | Strong public claims: tertiary Grade A, transplant qualifications, 46 clinical departments. | Public tertiary hospitals and broad private networks compete. | Need independent outcomes and volume by service line. |
| Service experience and private-care access | Social-run comprehensive hospital; satisfaction claim >95%. | United Family and other private networks compete on patient experience. | Need NPS method and patient cohort retention. |
| Price and reimbursement | 医保-designated but subject to pricing guidance/payment reform. | Public hospitals may be lower cost; specialty chains may optimize focused economics. | Need payer mix and margin sensitivity. |
| Digital/AI front door | Internet hospital and Dr.Shu/AI future hospital claims. | Digital-health platforms and hospital systems compete for online access. | Need adoption, retention and compliance/security evidence. |
Scoring is qualitative because no reliable public win/loss or local market-share data was available.
Qualitative map; not market-share analysis.
Public GTM signals are hospital-network access, online appointments/internet hospital, partner-hospital management output, media/founder visibility and clinical reputation; sales productivity and budget effectiveness are private.
partially verified confidence: medium
The public strategy appears to combine flagship-hospital brand, specialty clinical capabilities, internet services, media/founder visibility and partner-hospital output.
| channel | region or scope | public evidence | gap |
|---|---|---|---|
| Self-operated hospital front door | Hangzhou, Anji, Quzhou and planned/other facilities | Public sources describe Hangzhou/Anji/Quzhou operations and appointment services. | Patient acquisition source, conversion and site-level CAC not public. |
| Internet hospital and online services | Online / Hangzhou internet hospital | Internet hospital page and official hospital links. | Traffic, active users and online revenue not public. |
| Hospital-management output | Fujian, Hainan, Chongqing, Zhengzhou mentioned in 2021 | CICC cooperation description. | Contract revenue, renewal and partner-side confirmation missing. |
| Academic/international partnerships and clinical reputation | International and specialty centers | Official hospital introduction names collaboration institutions and medical centers. | Volume contribution and formal agreements missing. |
No channel weights or CAC/payback metrics were public.
| signal | evidence | strength | limitation |
|---|---|---|---|
| Hospital-owned service website | Public appointment, department, expert, internet service and report-query links. | Supports patient front-door presence. | Does not disclose conversion or satisfaction methodology. |
| IPO and financing media coverage | 36Kr and Eastmoney articles discuss financing, financials and IPO status. | Improves public visibility and diligence trail. | May expose governance and failed-IPO concerns. |
| Founder/AI thought-leadership profile | China News profile of Zheng Jie and Dr.Shu/AI future hospital. | Supports innovation narrative. | Adoption and clinical proof are not public. |
| Academician brand | Official pages feature Li Lanjuan and Zheng Shusen. | Brand credibility and specialist reputation. | Founders reportedly exited board; key-person economics need verification. |
Marketing table is qualitative; no campaign spend or lead-generation data was public.
No public conversion metrics were available.
not publicly verifiable confidence: low
Major customer status and pipeline are not public; for this provider model, diligence should focus on医保, commercial insurers, employer relationships, referral institutions and patient cohorts.
partially verified confidence: medium
Public avenues include hospital appointments, internet services, referrals, partner-hospital management, international collaboration and media-driven brand awareness.
not publicly verifiable confidence: low
Sales force compensation, quotas, cycle time and new-hire plans are not public. Hospital GTM likely depends on physician reputation, referral networks, online access and institutional partnerships.
not publicly verifiable confidence: low
Budget adequacy is not public; expansion losses and capex needs make marketing spend trade-offs important.
Public evidence supports research, clinical trials, digital hospital and AI ambition, but R&D budget, IP ownership, product adoption, security and clinical validation are not public.
partially verified confidence: medium
The R&D organization appears embedded in the hospital/clinical leadership, medical education, GCP, digital-health and founder-led AI/data initiatives; formal budget/headcount are not public.
| name or role | public role | relevance to r and d | source |
|---|---|---|---|
| Zheng Jie | Actual controller; founder/president in profile; digital-health/AI leader | HIS, OMAHA, Dr.Shu and AI future hospital narrative. | CICC; China News |
| Shou Zhangfei | President of Shulan (Hangzhou) Hospital; nephrology; clinical drug trial institution leader | Clinical-trial and transplant/renal expertise. | Official leadership page |
| Li Lanjuan and Zheng Shusen | Chinese Academy of Engineering academicians featured by hospital | Infectious disease, hepatobiliary surgery/transplant academic reputation. | Official academicians page |
| Hospital clinical/research departments | 46 clinical departments, 13 medical-technology departments, GCP qualification | Research, education, clinical trials and specialty centers. | Official hospital introduction |
Full R&D org chart, budgets and IP assignments were not public.
Counts are not a proxy for productivity.
partially verified confidence: medium
Public pipeline signals include Dr.Shu AI health agent, AI future hospital, intelligent hospital processes, GCP/clinical trials and organ-transplant/specialty centers; cost, timing and acceptance criteria are not public.
| project | public status | expected date or stage | verification or gap |
|---|---|---|---|
| Dr.Shu AI health agent | Reported launched in 2025 with conversational flows for appointment, report query and follow-up prescription. | 2025 public profile | Need product analytics, safety validation and regulatory review. |
| AI future hospital | Reported plan in Hangzhou combining compute cloud, 6G and mobile terminals. | Plan described in 2025 profile; no completion date public. | Need capex, budget, vendors, milestones and approvals. |
| Intelligent full-process hospital system | Official hospital intro describes cloud, big data, AI and IoT across pre/in/post-hospital workflows. | Active public claim | Need system architecture, uptime, cybersecurity and adoption. |
| Clinical trials and medical education | Hospital claims GCP qualification and medical/nursing education initiatives. | Active public claim | Need trials list, sponsors, revenue and compliance audits. |
Pipeline table does not imply commercial readiness.
Public sources identify the actual controller, founder-family succession and hospital leadership, but full org chart, compensation, incentive plans, headcount and turnover are not public.
partially verified confidence: medium
CICC identifies Zheng Jie as actual controller and official pages identify hospital executives; a complete group organization chart is not public.
| name | public role | tenure or background | source |
|---|---|---|---|
| Zheng Jie | Legal representative in 2021; actual controller; founder/president in China News profile | Zhejiang University computer background, TMT/digital-health profile; actual controller in CICC document. | CICC; China News |
| Zheng Jun | Family/control shareholder through Shanghai Shulan Investment; director referenced by media | Shanghai Shulan Investment ownership 40% in 2021 CICC table. | CICC; Eastmoney |
| Shou Zhangfei | President of Shulan (Hangzhou) Hospital | Medical doctor, chief physician, professor, nephrology and clinical drug trial leader. | Official leadership page |
| Feng Zhixian | Vice President of Shulan (Hangzhou) Hospital; nursing college/group nursing center | Chief nurse/professor; official page states 34 years work experience. | Official leadership page |
| Li Qiyong, Tang Lingling, Jiang Guoping, Zhang Wu, Sheng Guoping | Hospital vice presidents / specialty leaders | Official leadership page lists specialty clinical and academic roles. | Official leadership page |
| Li Lanjuan and Zheng Shusen | Academician founders/brand figures; reportedly exited board | Official hospital page features their academicianship and clinical/research credentials. | Official academicians page; Eastmoney governance paragraph |
Not a complete board or executive employment roster.
Formal reporting lines require company confirmation.
not publicly verifiable confidence: low
No public historical or projected headcount by function/location was available. Public signals include leadership rosters, clinical department counts and employee-benefit procurement notices.
| function or region | public evidence | status | private request |
|---|---|---|---|
| Clinical departments / Hangzhou | Official intro says 46 clinical and 13 medical-technology departments. | partially_verified | Headcount, vacancy, productivity and turnover by department. |
| Hospital leadership / Hangzhou | Official page lists at least seven hospital leaders. | verified for public roster | Employment agreements, succession and retention plans. |
| Digital/AI/product | China News profile describes HIS, Dr.Shu and AI future hospital but not team size. | partially_verified | Engineering/product headcount, contractors, security and hiring plan. |
| All locations/functions | No public HRIS or turnover data located. | not_publicly_verifiable | Monthly HRIS export for 2021-2026, open reqs, attrition and employee-relations log. |
No personal contact details are included.
No headcount values are fabricated.
partially verified confidence: medium
Public biographies are available for several hospital leaders and academicians; group executive biographies and current board bios are incomplete publicly.
not publicly verifiable confidence: low
No public employment agreements, key-clinician compensation, benefit plan or retention terms were available.
not publicly verifiable confidence: low
No current incentive stock plan, option pool, vesting or exercise-price schedule was public.
not publicly verifiable confidence: low
No public labor dispute or employee-relations issue was verified, but no court/labor-registry search artifacts or HR records were available.
not publicly verifiable confidence: low
No turnover data were public. Leadership pages show public roster snapshots, not retention trends.
Public legal diligence identifies regulated clinical capabilities, internet-hospital license signals,医保/DRG context, lapsed IPO process and a reported equity freeze, but lawsuits, IP ownership, material contracts, insurance and agency history require counsel-led review.
partially verified confidence: medium
No complete public litigation docket was obtained. A recent article reports an equity freeze involving the largest shareholder, which must be verified by counsel.
| matter | court or authority | date | status | diligence action |
|---|---|---|---|---|
| Equity freeze involving Shanghai Shulan Investment holding RMB 30M equity | Shanghai Pudong New Area People’s Court per media citing Tianyancha | 2026-02-13 | Cause not public in article | Counsel to pull court/registry record and assess effect on control/financing. |
| A-share counseling and HKEX prospectus lapse | CICC counseling; HKEX process referenced by media | 2021-2026 | Listing attempts reportedly stalled/failed | Request exchange correspondence, sponsor feedback and remediation plan. |
| Pending lawsuits against operating company | Not identified in accessible public sources | As of public-source screen | not_publicly_verifiable | PRC counsel docket search and management legal schedule. |
This table is not a court-docket search.
Likelihood ratings are analyst judgments based on public evidence strength.
not publicly verifiable confidence: low
No public schedule of lawsuits initiated by Shulan was found through accessible public sources.
| category | public evidence | verification status | request |
|---|---|---|---|
| Contract collections / supplier disputes | No public matters located in accessible sources. | not_publicly_verifiable | Provide docket list, collection actions and settlement history. |
| IP enforcement | No public company-initiated IP litigation located; IP register incomplete publicly. | not_publicly_verifiable | Provide IP enforcement, cease-and-desist and license disputes. |
| Medical malpractice defense/counterclaims | No public claims schedule available. | not_publicly_verifiable | Provide malpractice claims, insurance notices and clinical incident logs. |
Absence of public litigation evidence is not a no-litigation conclusion.
not publicly verifiable confidence: low
Public sources do not disclose environmental, occupational health or employee-safety liabilities; hospital operation creates inherent medical waste, infection-control and workplace safety obligations.
| asset or license | jurisdiction | public status | diligence caveat |
|---|---|---|---|
| Medical institution license/registration page | Hangzhou/Zhejiang/China | Official page includes 执业登记 section/image. | Need machine-readable license number, renewals and all facility licenses. |
| Internet drug information service qualification | Zhejiang/China | Certificate number （浙）-经营性-2023-0093 shown on internet hospital page. | Verify scope, renewal and any online prescription limits. |
| Organ-transplant qualifications and clinical trial institution qualification | China | Official intro claims liver, kidney, heart and lung transplant qualifications and GCP qualification. | Verify agency approvals, audit history and adverse events. |
| HIS, Dr.Shu, medical cloud, trademarks and patents | China / software and data jurisdictions | Publicly discussed, but registered rights and ownership not fully disclosed. | Need IP register, assignments, open-source scan, model/data rights and vendor contracts. |
| 医保定点 and DRG/DIP compliance | China local医保 jurisdictions | Official hospital says医保 designated; national policy imposes dynamic management and DRG/DIP coverage. | Need医保 agreements, audits, denial rates and payment-settlement records. |
This is not a substitute for PRC healthcare regulatory and IP counsel review.
partially verified confidence: medium
Public evidence shows license/regulated capability signals but not a complete IP register. AI, HIS, cloud platform and Dr.Shu require special attention to software/data ownership.
not publicly verifiable confidence: low
Insurance policies, malpractice coverage, D&O, cyber insurance and property/business-interruption coverage are not public.
| risk area | public evidence | severity | request |
|---|---|---|---|
| IPO/exchange and financing process | A-share counseling and lapsed HKEX process reported. | high | Exchange/sponsor correspondence and current listing/refinancing plan. |
| Equity freeze/control | RMB 30M equity freeze reported against Shanghai Shulan Investment stake. | high | Court order and resolution plan. |
| 医保 and DRG/DIP payment compliance | NHSA policies and Shulan医保-designated claim. | high | 医保 agreements, audits and payment reform sensitivity. |
| Clinical quality, malpractice and license renewals | High-acuity services and transplant/GCP claims. | high | Licenses, inspections, adverse events, malpractice claims and insurance. |
| Digital/AI/data/IP ownership | Internet hospital, Dr.Shu and medical cloud claims. | medium | Cybersecurity, data consent, IP assignments, model governance and vendor contracts. |
Crosswalk rows intentionally include legal matters and regulatory operating risks.
not publicly verifiable confidence: low
Material contracts are not public. Relevant contracts likely include hospital leases, construction, government subsidy,医保 agreements, supplier, physician, partner-hospital, clinical trial, cloud/software and investor agreements.
partially verified confidence: medium
No Shulan-specific agency sanctions were verified in public sources, but医保, DRG/DIP, medical licensing, clinical trials, transplant, internet hospital, data and AI governance are material regulatory domains.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Shulan Health as a private unicorn with a $1.24B valuation, joined 2021-03-01, China/Hangzhou, Healthcare & Life Sciences, with Qiming Venture Partners shown as a selected investor. | verified high | SRC-001 |
| EC-002 | Public media citing the prospectus reports Shulan completed five financing rounds, raised more than RMB 800M, and reached an RMB 8.0B valuation after a RMB 200M D round in March 2021. | partially verified medium | SRC-002SRC-003 |
| EC-003 | The 2021 CICC IPO counseling materials identify Shulan Health Management Co., Ltd. as founded on 2013-11-26, converted to a joint-stock company on 2020-12-01, with Zheng Jie as legal representative and registered capital/share capital of RMB 370.847372M. | verified high | SRC-004 |
| EC-004 | The 2021 CICC shareholder table shows Shanghai Shulan Investment holding 46.9067%, Cliff Investment/GIC holding 13.9337%, Suzhou Qiming Rongxin 2.2107%, and Shenzhen Sequoia Hanhchen 2.1866%; Zheng Jie was disclosed as actual controller. | verified high | SRC-004 |
| EC-005 | Public media citing the prospectus reports 2020-2022 revenue of RMB 1.618B, RMB 1.548B and RMB 1.778B; 2020 profit of RMB 64.1M; and 2021/2022 losses of RMB 82.3M and RMB 110.9M. | partially verified medium | SRC-002 |
| EC-006 | Eastmoney/Blue Whale reports 2021-2023 revenue grew from RMB 1.548B to RMB 1.884B, while the company remained loss-making; liabilities were RMB 3.226B, RMB 3.691B and RMB 2.607B with asset-liability ratios of 100%, 103% and 68%. | partially verified medium | SRC-003 |
| EC-007 | The official Shulan Hangzhou Hospital introduction describes it as a tertiary Grade A comprehensive hospital, the first large social-run comprehensive hospital in China to pass JCI 6th edition review,医保 designated, with 46 clinical departments, 13 medical-technology departments, major equipment, four organ-transplant qualifications, GCP qualification and patient satisfaction above 95%. | verified medium | SRC-005 |
| EC-008 | Shulan operates a public internet-hospital landing page showing ICP registration and an internet drug information service qualification certificate number. | verified medium | SRC-006 |
| EC-009 | Official Shulan pages identify senior Hangzhou Hospital leaders including Shou Zhangfei, Feng Zhixian, Li Qiyong, Tang Lingling, Jiang Guoping, Zhang Wu and Sheng Guoping, and separately feature academicians Li Lanjuan and Zheng Shusen. | verified medium | SRC-007SRC-008 |
| EC-010 | China News Shanghai profiles Zheng Jie as Shulan Medical Group founder/president and reports digital initiatives including OMAHA, a self-developed HIS, 2025 AI health agent Dr.Shu, and plans for an AI future hospital. | partially verified medium | SRC-009 |
| EC-011 | Public sources describe Shulan as a social-run medical group with health medical services, hospital management services and platform services; by 2023 it operated Hangzhou, Anji and Quzhou hospitals. | partially verified medium | SRC-002SRC-004 |
| EC-012 | A 2026 Eastmoney/Blue Whale article states Shulan’s A-share counseling ended without listing, its 2023 HKEX submission and 2024 updated prospectus had no further progress, the prospectus had lapsed, and a RMB 30M equity interest held by Shanghai Shulan Investment was frozen by Shanghai Pudong New Area People’s Court on 2026-02-13. | partially verified medium | SRC-003 |
| EC-013 | Eastmoney/Blue Whale reports Shulan’s self-operated hospitals, while private, must follow local pricing guidance for医保-covered services, drugs and consumables; health medical service gross margin was reported at 9.6% in 2021 and 8.5% in 2022, and average inpatient cost fell from RMB 21,300 in 2021 to RMB 17,500 in 2023. | partially verified medium | SRC-003 |
| EC-014 | NHSA’s DRG/DIP action plan targets coverage of all eligible inpatient medical institutions and broad disease/fund coverage by 2025, increasing payment-management discipline for hospital operators. | verified high | SRC-010 |
| EC-015 | NHSA policy says eligible private medical institutions may apply for医保定点 status under the same policy principles as public hospitals, while医保 departments should apply ongoing/dynamic management and protect医保 fund safety. | verified high | SRC-011 |
| EC-016 | Public competitor pages show Shulan competes with scaled Chinese private healthcare groups and specialty chains including United Family, Hygeia Healthcare and AIER Eye Hospital Group. | verified medium | SRC-012SRC-013SRC-014 |
| EC-017 | Public customer evidence consists mainly of patient-service and utilization claims; no top-15 customer, revenue-by-customer, payer mix, churn, NPS or reference-call evidence was found in public sources. | not publicly verifiable low | SRC-005SRC-006 |
| EC-018 | The flagship hospital claims cooperation with international medical institutions and experts, including UCLA, Massachusetts General Hospital, Princeton University, University of Hong Kong, Hong Kong Union Hospital and Macau University of Science and Technology. | partially verified medium | SRC-005 |
| EC-019 | The flagship hospital publicly claims research, education, GCP qualification, medical schools/colleges, and use of cloud, big data, AI and IoT to build a full-process intelligent health-service system. | partially verified medium | SRC-005 |
| EC-020 | CICC’s 2021 document states Shulan exports modern medical-construction capability to medical institutions in Fujian, Hainan, Chongqing and Zhengzhou and was building a group medical cloud platform. | partially verified medium | SRC-004 |
| EC-021 | Public materials identify licenses and regulated clinical capabilities, but material patents, trademarks, copyrights, land/house rights, data rights, insurance coverage and legal-matter schedules are not fully public. | not publicly verifiable low | SRC-004SRC-005SRC-006 |
| EC-022 | Public sources do not provide audited financial statements, cap table terms, debt instruments, AR aging, customer/payer concentration, employee data, contracts, security reports, litigation dockets or primary IP schedules. | not publicly verifiable low | SRC-001SRC-002SRC-003SRC-004SRC-005 |
| EC-023 | Public media reports that founders Li Lanjuan and Zheng Shusen exited the board, the current management is controlled by Zheng Jie and Zheng Jun through Shanghai Shulan Investment, and the transition resembles family succession. | partially verified medium | SRC-003SRC-004SRC-008 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | CB Insights: The Complete List Of Unicorn Companies | 2026-05-23 |
| SRC-002 | 36Kr / 直通IPO | 估值80亿，院士夫妻创办的医疗集团要IPO了 | 2026-05-23 |
| SRC-003 | 东方财富网 / 蓝鲸新闻 | 背靠院士光环树兰医疗两次IPO折戟，涉股权冻结，曾“超低价转股” | 2026-05-23 |
| SRC-004 | 中国国际金融股份有限公司 | 树兰医疗管理股份有限公司情况介绍及接受上市辅导公告 | 2026-05-23 |
| SRC-005 | 树兰（杭州）医院 | 树兰（杭州）医院医院介绍 | 2026-05-23 |
| SRC-006 | 树兰医疗 | 树兰（杭州）医院互联网医院 | 2026-05-23 |
| SRC-007 | 树兰（杭州）医院 | 树兰（杭州）医院领导班子 | 2026-05-23 |
| SRC-008 | 树兰（杭州）医院 | 树兰（杭州）医院院士风采 | 2026-05-23 |
| SRC-009 | 中新社上海 | 树兰医疗创始人郑杰：用“极客”思维重新定义现代医疗的践行者 | 2026-05-23 |
| SRC-010 | 中国政府网 / 国家医疗保障局 | 国家医疗保障局关于印发DRG/DIP支付方式改革三年行动计划的通知 | 2026-05-23 |
| SRC-011 | 北京市人民政府门户网站 / 国家医疗保障局 | 民营医院入医保不得随意设限：符合条件的均可申请纳入医保定点 | 2026-05-23 |
| SRC-012 | United Family Healthcare | United Family Healthcare About Us | 2026-05-23 |
| SRC-013 | Hygeia Healthcare Holdings Co., Limited | Hygeia Healthcare official profile | 2026-05-23 |
| SRC-014 | AIER / Sichuan Eye Hospital | AIER Eye Hospital Group profile | 2026-05-23 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.